- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05726734
Vonoprazan-containing Triple Therapy Versus Empiric Bismuth Quadruple Therapy for First-line Helicobacter Pylori Treatment: a Randomized Clinical Trial
February 3, 2023 updated by: Yingjie Ji, Shanghai East Hospital
Efficacy of Vonoprazan-containing Triple Therapy Versus Empiric Bismuth Quadruple Therapy for First-line Helicobacter Pylori Treatment: a Randomized Clinical Trial
Vonoprazan Amoxicillin and metronidazole based triple therapy had achieved a high cure rate in the rescue treatment of helicobacter pylori infection.
This study aims to evaluate the efficacy and safety of the Vonoprazan, amoxicillin and metronidazole based triple therapy and the empiric bismuth quadruple therapy in the naive patients with Helicobacter pylori infection.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
100
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yingjie Ji, M.D.
- Phone Number: +86-15800575527
- Email: jiyingjie39@outlook.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200120
- Shanghai East Hospital
-
Sub-Investigator:
- Qinwei Xu
-
Sub-Investigator:
- Xinyan Zhu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Participants with non-ulcer functional dyspepsia or peptic ulcer disease
- Ability and willingness to participate in the study and to sign and give informed consent
- Confirmed H. pylori infection and with no previous treatment experience
Exclusion Criteria:
- Less than 18 years old
- With previous gastric surgery
- Major systemic diseases
- Pregnancy or lactation
- Allergy to any of the study drugs Administration of antibiotics, bismuth, antisecretory drugs in 8 weeks prior to inclusion
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Vonoprazan-containing Triple Therapy
Vonoprazan 20mg bid, Amoxicillin 1.0g tid and Metronidazole 0.4g tid for 14 days
|
Antibiotics for H. pylori eradication
potassium-competitive acid blocker
|
EXPERIMENTAL: Empiric Bismuth Quadruple Therapy
Esomeprazole 20mg bid, Bismuth Potassium Citrate 600mg bid, Amoxicillin 1.0g tid and Metronidazole 0.4g tid for 14 days
|
Proton pump inhibitor
Gastric mucosal protective drug with anti-H.
pylori effect
Antibiotics for H. pylori eradication
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Helicobacter pylori eradication rate
Time Frame: Six weeks after completion of therapy
|
Six weeks after completion of therapy, H. pylori eradication was assessed by ¹³C-urea breath test.
Eradication was defined as negative result from urea breath test (<4‰) (4‰ as the cutoff value).
|
Six weeks after completion of therapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of adverse effects
Time Frame: Within 7 days after completion of therapy
|
The subjects were asked to grade the severity of adverse events according to their influence on daily activities, experienced as "mild" (transient and well tolerated), "moderate" (causing discomfort and partially interfering with daily activities), or "severe" (causing considerable interference with daily activities)
|
Within 7 days after completion of therapy
|
Compliance rate
Time Frame: Within 7 days after completion of therapy
|
Compliance was defined as poor when they had taken less than 80% of the total medication
|
Within 7 days after completion of therapy
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Yingjie Ji, M.D., Shanghai East Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
February 6, 2023
Primary Completion (ANTICIPATED)
February 6, 2025
Study Completion (ANTICIPATED)
February 6, 2026
Study Registration Dates
First Submitted
February 3, 2023
First Submitted That Met QC Criteria
February 3, 2023
First Posted (ESTIMATE)
February 14, 2023
Study Record Updates
Last Update Posted (ESTIMATE)
February 14, 2023
Last Update Submitted That Met QC Criteria
February 3, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Gram-Negative Bacterial Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Infections
- Helicobacter Infections
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Gastrointestinal Agents
- Natriuretic Agents
- Anti-Bacterial Agents
- Diuretics
- Respiratory System Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- Anti-Ulcer Agents
- Proton Pump Inhibitors
- Expectorants
- Antacids
- Metronidazole
- Amoxicillin
- Esomeprazole
- Bismuth
- Potassium Citrate
Other Study ID Numbers
- 2022150
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Helicobacter Pylori Infection
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...RecruitingHelicobacter Pylori Infection | Helicobacter Pylori EradicationBangladesh
-
Shandong UniversityRecruitingHelicobacter Pylori Infection | Patient Education | Helicobacter Pylori EradicationChina
-
Shandong UniversityCompletedHelicobacter Pylori Infection Helicobacter Pylori Eradication Patient EducationChina
-
Shanghai Jiao Tong University School of MedicineCompletedCure Rate of Helicobacter Pylori InfectionChina
-
Seoul National University Bundang HospitalRecruitingHelicobacter Pylori Infection | Helicobacter Pylori 23S rRNA Clarithromycin Resistance Mutation | Helicobacter Pylori Associated Gastrointestinal Disease | Helicobacter Pylori Infection, Susceptibility toKorea, Republic of
-
The First Affiliated Hospital of Nanchang UniversityUnknownBacterial Infection Due to Helicobacter Pylori (H. Pylori) | Eradication Therapy of Helicobacter Pylori | Detection of Helicobacter PyloriChina
-
Tanta UniversityNot yet recruitingPersistent Helicobacter Pylori InfectionEgypt
-
Nanjing First Hospital, Nanjing Medical UniversityCompletedHelicobacter Pylori 23S rRNA/gyrA Gene Mutation Detection Kit (Fluorescence PCR Fusion Curve Method)Helicobacter Pylori Infection | Helicobacter Pylori gyrA Levofloxacin Resistance Mutation | Fecal Drug Resistance Gene Detection | Helicobacter Pylori Infection, Susceptibility toChina
-
Kaohsiung Veterans General Hospital.Kaohsiung Medical University Chung-Ho Memorial HospitalCompletedHelicobacter Pylori InfectionTaiwan
-
National Taiwan University HospitalCompleted
Clinical Trials on Esomeprazole
-
TakedaCompletedHealthy ParticipantsUnited States
-
National Taiwan University HospitalMinistry of Science and Technology, Taipei, TaiwanCompleted
-
Chinese University of Hong KongCompletedBleeding | Peptic UlcerChina
-
AstraZenecaCompletedRefractory Reflux EsophagitisJapan
-
Bio-innova Co., LtdNot yet recruiting
-
Onconic Therapeutics Inc.Completed
-
Bio-innova Co., LtdNot yet recruiting
-
Chong Kun Dang PharmaceuticalCompleted
-
AstraZenecaCompletedGastroesophageal Reflux Disease (GERD)United States, France, Poland, Germany
-
Chinese University of Hong KongTerminatedGastrointestinal HemorrhageChina